Tag Archives: breast

Platinum agent combination treatment for triple-negative breast cancer well tolerated in phase II clinical trial — ScienceDaily

Triple-negative breast cancer is characterized by the absence of estrogen and progesterone receptors and the HER2/neu protein in breast cancer cells. That in itself presents a challenge in treating the disease, as it does not respond to hormonal- or HER2-targeted therapies that provide for positive outcomes in other subtypes of breast cancer. Triple-negative breast cancers are often deficient in DNA repair and other specific cellular pathways that make them susceptible to DNA damage. There is growing evidence that suggests platinum-based agents may offer improved outcomes in treating the subset of triple-negative breast cancer because of their specificity for causing DNA damage…

Platinum agent combination treatment for triple-negative breast cancer well tolerated in phase II clinical trial

Triple-negative breast cancer is characterized by the absence of estrogen and progesterone receptors and the HER2/neu protein in breast cancer cells. That in itself presents a challenge in treating the disease, as it does not respond to hormonal- or HER2-targeted therapies that provide for positive outcomes in other subtypes of breast cancer. …

Boosting length of breastfeeding could save NHS more than �40 million every year — ScienceDaily

The numbers add up to a strong economic case to invest in services to support mums to carry on breastfeeding, they conclude. In common with many other high income countries, breastfeeding rates in the UK are low, and to find out if boosting these could cut healthcare costs by improving mother and child health, the researchers focused on five priority diseases. They looked at the financial impact of not breastfeeding on gastrointestinal and lower respiratory tract infections; the ear infection otitis media in infants; the potentially lethal gut disorder necrotising enterocolitis in preterm babies; and lifetime risk of breast cancer in mothers…

Prognostic role found for miR-21 expression in triple-negative breast cancer — ScienceDaily

TNBC accounts for 15% to 20% of breast cancer cases, and patients have shorter recurrence-free survival (RFS) and breast cancer-specific survival (CSS) relative to other major subgroups. It is likely that different subtypes of TNBCs exist, and the heterogeneity may be responsible for a wide variation in response to treatment. “Predictive biomarkers for therapeutic response prediction and novel therapeutic targets that address distinct biological features of TNBC subgroups are needed for these patients,” says Lorenzo F. Sempere, PhD, head of the Laboratory of microRNA Diagnostics and Therapeutics at Van Andel Research Institute in Grand Rapids, MI. …

Prognostic role found for miR-21 expression in triple-negative breast cancer

TNBC accounts for 15% to 20% of breast cancer cases, and patients have shorter recurrence-free survival (RFS) and breast cancer-specific survival (CSS) relative to other major subgroups. It is likely that different subtypes of TNBCs exist, and the heterogeneity may be responsible for a wide variation in response to treatment. “Predictive biomarkers for therapeutic response prediction and novel therapeutic targets that address distinct biological features of TNBC subgroups are needed for these patients,” says Lorenzo F. …

HIV drug blocks bone metastases in prostate cancer — ScienceDaily

“Because this work shows we can dramatically reduce metastasis in pre-clinical models, and because the drug is already FDA approved for HIV treatment- we may be able to test soon whether this drug can block metastasis in patients with prostate cancer,” says Richard Pestell, M.D., Ph.D., MBA, Director of the Sidney Kimmel Cancer Center at Thomas Jefferson University and senior author on the study. The work builds on previous research from Dr. Pestell’s lab that showed in 2012 that CCR5 signaling was key in the spread of aggressive forms of breast cancer to the lungs…

Gene associated with an aggressive breast cancer uncovered — ScienceDaily

TNBC is deadly because, unlike other types of breast cancers such as estrogen receptor (ER) positive or HER2 amplified breast tumours which have effective targeted therapy, TNBC tumours do not respond to targeted therapy. Breast cancer has many subtypes, each with its own genetic makeup. …

Gene linked to tamoxifen-resistant breast cancers — ScienceDaily

The gene, called MACROD2, might also be useful in screening for some aggressive forms of breast cancers, and, someday, offering a new target for therapy, says Ben Ho Park, M.D., Ph.D., an associate professor of oncology in the Kimmel Cancer Center’s Breast Cancer Program and a member of the research team. The drug tamoxifen is used to treat estrogen receptor-positive breast cancers. Cells in this type of breast cancer produce protein receptors in their nuclei which bind to and grow in response to the hormone estrogen. Tamoxifen generally blocks the binding process of the estrogen-receptor, but some estrogen receptor-positive cancers are resistant or become resistant to tamoxifen therapy, finding ways to elude its effects…

Saving ovaries does not help prevent prolapse for women after menopause

Whether to remove ovaries at hysterectomy for reasons other than cancer is a subject of hot debate. Removing them reduces the risk of breast cancer and dramatically reduces the risk of ovarian cancer. On the other hand, studies have associated removing ovaries with increased risk of death, cardiovascular disease, lung cancer, and osteoporosis and with declines in cognitive ability and sexual function. And many assumed that removing ovaries would also increase the risk of pelvic organ prolapse. …